Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
2019 · The Lancet · 556 citations
https://doi.org/10.1016/s0140-6736(18)31791-4